Johnson & Johnson, Eli Lilly, Sanofi and Bristol Myers Squibb are suing the federal government over the future of their 340B drug rebate plans. The lawsuits reflect rising tensions among drugmakers, ...
The 340B Drug Pricing Program was designed to help safety net providers serve low-income patients, but it has since ballooned into a multibillion-dollar system dominated by large health systems — with ...
MedPage Today on MSN
Hospitals, drugmakers, and US government continue battle over 340B program
The drug discount program is under scrutiny on a variety of fronts ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results